Cargando…

Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy

PURPOSE: We aimed to analyze and evaluate the safety signals of ribavirin-interferon combination through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS), so as to provide reference for the rationale use of these agents in the management of relevant toxicitie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shan, Wenya, Hong, Dongsheng, Zhu, Jieqiang, Zhao, Qingwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532425/ https://www.ncbi.nlm.nih.gov/pubmed/33029193 http://dx.doi.org/10.1155/2020/1391583

Ejemplares similares

Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
por: Falzarano, Darryl, et al.
Publicado: (2013)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Adverse Skin Reactions due to Ribavirin in Hepatitis C Combination Therapy with Pegylated Interferon-α(2a)
por: Shindo, Masahisa, et al.
Publicado: (2013)

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol
por: Zeng, Yan-Ming, et al.
Publicado: (2020)

Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
por: Aizawa, Nobuhiro, et al.
Publicado: (2013)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19
por: Khalili, Jahan S., et al.
Publicado: (2020)

Cutaneous side effects of combination therapy of pegylated interferon 2α and ribavirin
por: Raducan, Anca, et al.
Publicado: (2014)

Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection
por: Shimojima, Masayuki, et al.
Publicado: (2015)

Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study
por: Al-Tawfiq, Jaffar A., et al.
Publicado: (2014)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
por: Akram, Madiha, et al.
Publicado: (2011)

Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines
por: Morgenstern, Birgit, et al.
Publicado: (2005)

Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]
por: Veldt, Bart J, et al.
Publicado: (2003)

Clearance of HCV by Combination Therapy of Pegylated Interferon α-2a and Ribavirin Improves Insulin Resistance
por: Kim, Hong Joo, et al.
Publicado: (2009)

Genetic Variability of Hepatitis C Virus before and after Combined Therapy of Interferon plus Ribavirin
por: Cuevas, José Manuel, et al.
Publicado: (2008)

Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?
por: Pourhoseingholi, Mohamad Amin, et al.
Publicado: (2014)

Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C
por: Zaily, Dorta Guridi, et al.
Publicado: (2017)

Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C
por: Rashed, Yasser K., et al.
Publicado: (2020)

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
por: Meyer, Douglas F., et al.
Publicado: (2010)

Efficacy of pegylated interferon plus ribavirin in combination with corticosteroid for two cases of combined hepatitis C and autoimmune hepatitis
por: Oeda, Satoshi, et al.
Publicado: (2012)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
por: Cho, Hyun Chin, et al.
Publicado: (2013)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
por: Carvalho-Filho, Roberto J, et al.
Publicado: (2010)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
por: Chopra, Amit, et al.
Publicado: (2015)

The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients
por: Jung, Hee Jae, et al.
Publicado: (2014)

Polymorphisms of HLA-DM on Treatment Response to Interferon/Ribavirin in Patients with Chronic Hepatitis C Virus Type 1 Infection
por: Chen, Hongbo, et al.
Publicado: (2016)

Pneumonitis as A Consequence of (Peg)Interferon-Ribavirin Combination Therapy for Hepatitis C: a Review of the Literature
por: Slavenburg, Serena, et al.
Publicado: (2009)

Takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon-alpha and ribavirin for chronic hepatitis C
por: Martin, Carmen Sorina, et al.
Publicado: (2014)

Anti-tumor effect of ribavirin in combination with interferon-α on renal cell carcinoma cell lines in vitro
por: Teng, Lichen, et al.
Publicado: (2014)

Meta-Analysis of Combination Therapy of Chinese Herbs Plus Interferon and Ribavirin in Patients with Chronic Hepatitis C
por: Wang, Jianjun, et al.
Publicado: (2016)

Treatment of chronic hepatitis C patients not responding to combination therapy with ribavirin and interferon α — hype or hope?
por: Vogel, Wolfgang
Publicado: (2004)

Clinical Outcomes of Japanese Encephalitis after Combination Treatment of Immunoglobulin, Ribavirin, and Interferon-α2b
por: Son, Hyoshin, et al.
Publicado: (2021)

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
por: You, Byung Chul, et al.
Publicado: (2012)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
por: Chak, Eric, et al.
Publicado: (2010)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012)

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study
por: Omrani, Ali S, et al.
Publicado: (2014)

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens
por: Younossi, Zobair M., et al.
Publicado: (2016)

The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination Interferon-α2β and Ribavirin
por: Tran, Huy A, et al.
Publicado: (2005)

Fatal Neutropenic Enterocolitis during Pegylated Interferon and Ribavirin Combination Therapy for Chronic Hepatitis C Virus Infection
por: Kim, Ji Hun, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_c586jtcf7hbp1ltm13isb86shb